The Myeloma Beacon

Independent, up-to-date news and information for the multiple myeloma community.
Home page Deutsche Artikel Artículos Españoles

Forums

General questions and discussion about multiple myeloma (i.e., symptoms, lab results, news, etc.) If unsure where to post, use this discussion area.

Help with cytogenetics and maintenance therapy choice

by Charles Lewis on Wed Feb 12, 2014 4:10 pm

I was diagnosed with MMY 8 months ago. I'd had back pain for many months before the doctors finally figured out the true cause. I had an aggressive presentation. I was in renal failure and had many lesions, though no fractures. My bone marrow was 40% myeloma cells. I have done very well since, however. My kidney function quickly normalized and stayed there (creatinine of 1.1 or so). I had three rounds of chemo (Velcade, cytoxin, dex), then high dose chemo and stem-cell transplant. I am now in CR and have been for several weeks.

The question is what I should do for maintenance? Velcade, Revlimid, or both. I was told by my primary doctor last July that I was high-risk based on my cytogenetics report. After repeated requests, I recently reviewed a copy of the actual cytogenetics/FISH report at the time of my diagnosis in June 2013 and have very serious doubts that I have been properly classified. My FISH report of 200 cells was completely negative for ANY bad cellular abnormalities: No 17p13.1 deletions, no 13 deletions, no 1 p32.3/CDKN2C deletion, no ! q21/CKS1B amplification. I did have 9.5% cells (19 out of 200) with translocation 11:14, but that is considered neutral or favorable from everything I've read.

On the other hand, cytogenetics showed one bad cell out of 20. The single bad cell showed a deletion of 13, various chromosome 1 abnormalities, the 11:14 translocation, and gains on 19 and 21. The chromosome 1 abnormalities were not inconsistent with FISH. They involved deletions on parts 1p12 and 1 q 12. My research has revealed that the deletion of part 12 of chromosome has a de minimis impact on survival (unlike part 32.3), and I do not have the 1q amplification. From what I gather the gains on 19 and 21 are favorable and could offset the single bad cell's unfavorable features. In interpreting the cytogenetics, the pathology report only said the following:

"One abnormal and 19 normal male metaphases are analyzed. The single abnormal metaphase exhibiting hyerptetrapoidly with an apparent der (14)t (11:14) represents clonal aberration which was consistent with the FISH studies....Abnormalities involving gains of chromosome 19, 21, and structural abnormaiities of 11q and 14q have all been associated with a diagnosis of Myeloma. FISH results to follow."

The interpretative part of the pathology report did not even mention chromosomes 1 or 13.

My main doctor has recommended that I do Velcade maintenance, or a combo study with oral Velcade (MLN 9078) and Revlimid because of the chromosome 1 and 13 abnormalities on cytogenetics. In calculating the best course of action for me for maintenance, should I really look at myself as high-risk? From what I've seen, the 13 deletion by cytogenetics is generally considered intermediate risk, but I only have one cell out of several hundred. Responding to another post on this forum, a doctor wrote "In general when a patient meets the criteria, it will be stated as so in the pathology report. Generally a specific percentage of cells must be affected by the genetic finding to be clinically important." I have seen other studies in which at least 10% of cells must be affected for the abnormality to be accorded significance.

Last September, I was fretting about my bad cytogenetics with a different doctor, the one who supervised my stem-cell transplant. He told me that I had only one abnormal cell out of 20 and many places would not consider me high-risk; however, they had discovered that even a single cell could have an impact. I did not realize at that time that I had actually had 200 cells checked (not 20) and the percentage of cells with a bad abnormality was .5% (not 5%).

Can a bad strain or clone be inferred from a single cell? Should I properly be treated as regular-risk, intermediate risk, or high-risk based on the initial cytogenetics/FISH?. Has anyone else out there had a single abnormal cell with bad characteristics out of several hundred cells check. Have any doctors out there had patients with a single bad cell? How were they classified and treated?

Thanks to all for your feedback.

P.S. I had another biopsy last September, and the cytogenetics/FISH were completely normal, not even the 11:14 translocation.

Charles Lewis

Charles Lewis

Return to Multiple Myeloma